

December 4, 2024

The Manager- Listing  
**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra – Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received an order from the Income-tax Appellate Tribunal (“ITAT”) issued under section 254 of the Income Tax Act, 1961 for the assessment year 2017-18 and 2018-19 on December 3, 2024.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You  
**For AstraZeneca Pharma India Limited**

Manasa R  
Company Secretary

**Annexure – A**

Sl. No.	Particulars	Details
1.	Name of the opposing party	Assistant/ Deputy Commissioner of Income-Tax, Circle-1(1)(1), Bangalore
2.	Brief details of dispute/litigation	Company has received an order from the ITAT issued under section 254 of the Income Tax Act, 1961 for the assessment year 2017-18 and 2018-19. The order has been passed pursuant to the appeal filed by the Company against the final assessment order passed by the Tax Officer for the captioned years. The order has been pronounced on three grounds, two being the corporate tax ground and one being the transfer pricing ground. On the corporate tax grounds, complete relief has been provided by the ITAT. On the transfer pricing ground, the ITAT has remitted the matter back to the Assessing Officer to review and pass the order in line with the directions given by the ITAT.
3.	Court/tribunal/agency where the litigation is filed	Appeal was filed before ITAT against which the ITAT has passed the captioned order. Now, the Company would take up the matter with the Assessing Officer to pass the order in line with the directions provided by the ITAT.
4.	Expected financial implications, if any, due to compensation, penalty etc.	The expected overall financial implication cannot be determined at this stage. However, the estimated favorable tax impact on account of the captioned ITAT order could be Rs. 35.01 crores (approx.).
5.	Quantum of claims, if any	NA